CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,619 | +34.0% | 39,604 | +38.6% | 0.00% | 0.0% |
| Q1 2024 | $1,208 | -0.2% | 28,579 | +0.2% | 0.00% | 0.0% |
| Q4 2023 | $1,210 | +104.0% | 28,535 | +5.1% | 0.00% | +100.0% |
| Q3 2023 | $593 | -30.8% | 27,152 | +0.8% | 0.00% | 0.0% |
| Q2 2023 | $857 | +15.2% | 26,945 | -11.6% | 0.00% | 0.0% |
| Q1 2023 | $744 | -42.7% | 30,487 | -26.0% | 0.00% | -50.0% |
| Q4 2022 | $1,299 | -99.9% | 41,171 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,163,000 | +15.7% | 41,152 | +8.3% | 0.00% | +100.0% |
| Q2 2022 | $1,005,000 | -5.7% | 38,006 | +24.8% | 0.00% | 0.0% |
| Q1 2022 | $1,066,000 | +15.2% | 30,454 | +6.8% | 0.00% | 0.0% |
| Q4 2021 | $925,000 | +23.2% | 28,526 | +12.0% | 0.00% | 0.0% |
| Q3 2021 | $751,000 | -3.0% | 25,467 | -15.7% | 0.00% | 0.0% |
| Q2 2021 | $774,000 | – | 30,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 65,679,781 | $2,685,646,245 | 57.02% |
| Twin Securities, Inc. | 416,657 | $17,037,105 | 13.40% |
| Sand Grove Capital Management LLP | 919,023 | $37,578,850 | 10.99% |
| Perceptive Advisors | 10,794,876 | $441,402,480 | 10.63% |
| P SCHOENFELD ASSET MANAGEMENT LP | 796,440 | $32,566,432 | 7.87% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,353,694 | $96,242,547 | 4.60% |
| Avoro Capital Advisors LLC | 7,539,547 | $308,292,077 | 4.11% |
| Melqart Asset Management (UK) Ltd | 1,099,229 | $44,947,474 | 3.72% |
| Paradigm Biocapital Advisors LP | 2,330,508 | $95,294,472 | 3.65% |
| WATER ISLAND CAPITAL LLC | 766,933 | $31,360 | 3.33% |